It was reported the patient developed venous thromboembolism (vte) after a spectrum turbo-ject single lumen minocycline/rifampin bedside power-injectable picc was placed.The line clotted between day three and four after placed.As reported, the drop was at the optimal tip position and inserted into veins of optimal size for selected catheters with no issues.It is unknown if the reported device will be returned.To date, additional information regarding the event, device lot and current patient status has been requested but not provided.
|
Date of event estimated to be (b)(6) 2018, reported event occurred 3-4 days after placement.Additional information received identified the picc line placement procedure took place (b)(6) 2018.It was also reported the procedure entailed one attempt in the left brachial cut at 30 cm with optimal position.Additionally, it was reported the catheter was removed and replaced by exchange over a wire with another one.The reporter stated the patient was a difficult patient and the vte may or may not have been caused by the type of picc placed.(b)(4).
|
Blank fields on this form indicate the information is unknown, unavailable or has been previously reported.Investigation - evaluation: the complaint device was not returned; therefore no physical examination could be performed.There is no evidence to suggest the device was not manufactured to specifications, and there is no evidence to suggest the catheter was placed incorrectly.The facility also reported that the patient involved was known to be difficult and it is possible the device did not cause the adverse event.The ifu shipped with this device gives information based on preliminary reports that describe the relationship between catheter size and potential for clot formation.The manufacturing and quality control documents for the wire guide were reviewed, and the appropriate controls are in place to ensure the device is manufactured to specifications.The device history record was reviewed and no related non-conformities were found.There is no evidence to suggest the device was not manufactured to specifications.There have been no additional reported complaints associated with the product lot.There is no evidence to suggest there are non-conforming devices in house or in field.Based on the information provided, no product returned, and the results of our investigation, a definitive root cause could not be determined.Per the [quality engineering] risk assessment, no further action is required.Monitoring will continue to be performed for similar complaints.This report is required by the fda under 21 cfr part 803 and is based on unconfirmed information submitted by others.Neither the submission of this report nor any statement contained herein is intended to be an admission that any cook device is defective or malfunctioned, that a death or serious injury occurred, nor that any cook device caused, contributed to, or is likely to cause or contribute to a death or serious injury if a malfunction occurred.
|